ABBVIE INC (ABBV)
Sector: Health Care
2026 Annual Meeting Analysis
ABBVIE INC · Meeting: May 8, 2026
Directors FOR
4
Directors AGAINST
0
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of Directors
Ms. Davis joined the board in 2023 (within 24 months of the meeting), so she is exempt from the TSR trigger; she brings relevant healthcare and consumer strategy experience from her senior leadership role at Procter & Gamble, no overboarding concerns, and attended all meetings.
Ms. Meyer has served since 2017 and the 3-year TSR gap versus the peer group is -20.7pp, well below the 65pp threshold required to trigger a vote against for strong positive absolute TSR; she holds two public board seats (AbbVie and bp, with the bp term ending April 2026) so no overboarding concern, and attended all meetings.
Mr. Michael became a director in 2024 (within 24 months of the meeting date), so he is exempt from the TSR trigger; as CEO and Chairman he brings deep operational knowledge of AbbVie, and no other policy triggers apply.
Mr. Waddell has served since 2013 and the 3-year TSR gap versus the disclosed peer group is -20.7pp, far below the 65pp threshold required to trigger a vote against given AbbVie's strong positive 3-year absolute TSR of +46.5%; he holds two public board seats (AbbVie and IBM), attended all meetings, and chairs the Audit Committee with financial expertise confirmed.
All four Class II nominees pass the policy screens. AbbVie's 3-year absolute TSR of +46.5% places it in the strong-positive tier, requiring a 65pp underperformance gap versus the peer group to trigger a vote against; the actual gap is only -20.7pp. No director is overboarded, attendance is strong across the board, and all nominees have relevant qualifications.
Say on Pay
✓ FORCEO
Robert A. Michael
Total Comp
$32,530,984
Prior Support
93.1%%
CEO total compensation of approximately $32.5 million is substantial but reflects a first full year as CEO and Chairman of a $363 billion company, and pay mix is heavily performance-based — more than 75% of NEO pay is variable, tied to multi-year earnings per share growth, relative return on invested capital, and relative total shareholder return, all of which are strong long-term metrics. AbbVie delivered total shareholder returns of +46.5% over three years and +139.2% over five years, supporting that incentive pay above benchmark reflects genuine performance alignment rather than a disconnect. Prior-year Say on Pay support was 93.1%, indicating strong and consistent shareholder endorsement of the program structure.
Auditor Ratification
✓ FORAuditor
Ernst & Young LLP
Tenure
13 yrs
Audit Fees
N/A
Non-Audit Fees
N/A
Ernst & Young has served as AbbVie's auditor since 2013 (approximately 13 years), well below the 25-year tenure threshold that would raise independence concerns; the proxy does not provide a fee breakdown in the excerpted text but discloses no material restatements or auditor adequacy concerns, and EY is a Big 4 firm appropriate for a company of AbbVie's size and complexity.
Stockholder Proposals
1 proposal submitted by shareholders
Proposal 5
Stockholder Proposal on Independent Board Chair
The filers are faith-based and values-aligned institutional investors rather than ideological advocacy groups in the strict sense, so the proposal is evaluated on its merits as a governance structural request. While an independent board chair is a legitimate governance preference, AbbVie already has a strong governance substitute: 12 of 13 directors are independent, all board committees are fully independent, and the Lead Independent Director has robust, formally defined responsibilities including leading CEO evaluation, setting board agendas, and engaging directly with shareholders. Prior-year support for this type of proposal has consistently remained around 30% or below at AbbVie and across the S&P 500 in 2025, indicating that shareholders are not signaling a pressing concern, and the company's 10-year TSR of +485% under the combined structure undermines the argument that the current leadership model is failing shareholders.
Overall Assessment
AbbVie's 2026 annual meeting ballot is straightforward and largely supportable: all four director nominees pass policy screens, the compensation program is heavily performance-based with strong prior-year shareholder endorsement, and the board's supermajority elimination proposal is a genuine governance improvement. The only close call is the independent chair stockholder proposal, which fails to clear the bar given AbbVie's robust Lead Independent Director structure, consistent low prior-year support, and strong long-term performance under the combined CEO/Chair model.
Compensation Peer Group
9 companies disclosed in 2026 proxy filing